Freire-Alvarez, Eric http://orcid.org/0000-0002-1748-0325
Vanni, Paola http://orcid.org/0000-0002-5787-8872
Kurča, Egon
Lopez-Manzanares, Lydia http://orcid.org/0000-0003-4615-4542
Kovács, Norbert http://orcid.org/0000-0002-7332-9240
Spanaki, Cleanthe
Gao, Tianming
Bergmann, Lars
Sánchez-Soliño, Olga
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
https://doi.org/10.1007/s40120-024-00583-z
2611 Dyskinesia signs and symptoms, and quality of life in Parkinson’s Disease: post hoc analysis from the DYSCOVER study
https://doi.org/10.1136/bmjno-2023-anzan.52
Article History
Received: 27 November 2023
Accepted: 16 January 2024
First Online: 12 February 2024
Declarations
:
: Eric Freire-Alvarez has received advisory, consulting, and lecture fees from AbbVie, Bial, Neuraxpharm, Teva, and Zambon, and was an investigator on the DYSCOVER study. He is an investigator on studies funded by AbbVie, Anavex, Bial, Cerevel, Impax, Irlab, Neuroderm, Roche, and Zambon. Paola Vanni has received speaker fees from AbbVie, Bial, Italfarmaco, and Piam; research grant support from AbbVie and Piam; and technical and logistical support from Medtronic, Pfizer, Sanofi, Teva, UCB, and Zambon. She was an investigator on the DYSCOVER study. Egon Kurča was an investigator on the DYSCOVER study. Lydia Lopez-Manzanares has been compensated for advisory services and has received consulting, research grant support, or speaker honoraria from AbbVie, Abbott, Bial, Italfarmaco, Krka, Lundbeck, Roche, Stada, and Zambon. She was an investigator on the DYSCOVER study. Norbert Kovács has received honorarium from AbbVie, Abbott, Boston Scientific, GlaxoSmithKline, Krka, MEdis, Medtronic, Richter Gedeon, and UCB for lecturing at symposia. He has been a consultant for AbbVie, Abbott, KrKa, and Teva, and has received research funding from Abbott; the Hungarian National Research, Development and Innovation Office; University of Pécs; and Medtronic. He was an investigator on the DYSCOVER study. Cleanthe Spanaki has received honoraria for lecturing, advisory fees, educational grants, and travel grants from AbbVie, ITF Hellas, Merck Serono, and Teva, and was an investigator on the DYSCOVER study. Tianming Gao, Lars Bergmann, and Olga Sánchez-Soliño are employees of AbbVie and may hold AbbVie stock and/or stock options.
: Patients provided written informed consent before enrollment. Institutional review boards and ethics committees approved the DYSCOVER study protocol at all study sites in participating countries. This clinical study was conducted in accordance with the Good Clinical Practice guideline as defined by the International Council for Harmonisation guidelines, Declaration of Helsinki of 1964 and its later amendments, institutional review boards, and all applicable regional regulations. Where applicable, permissions were obtained to use the scales and assessment measures employed in this clinical trial (UDysRS, KPPS, PDQ-8, UPDRS II, CGI-S, CGI-C, and PD diary).